Cargando…

Evaluation of 4β-Hydroxycholesterol as a Clinical Biomarker of CYP3A4 Drug Interactions Using a Bayesian Mechanism–Based Pharmacometric Model

A Bayesian mechanism–based pharmacokinetic/pharmacodynamic model of cytochrome P450 3A4 (CYP3A4) activity was developed based on a clinical study of the effects of ketoconazole and rifampin on midazolam exposure and plasma 4β-hydroxycholesterol (4βHC) concentrations. Simulations from the model demon...

Descripción completa

Detalles Bibliográficos
Autores principales:	Leil, T A, Kasichayanula, S, Boulton, D W, LaCreta, F
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2014
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4076805/ https://www.ncbi.nlm.nih.gov/pubmed/24964282 http://dx.doi.org/10.1038/psp.2014.18

Ejemplares similares

No Impact of Vitamin D on the CYP3A Biomarker 4β-Hydroxycholesterol in Patients with Abnormal Glucose Regulation
por: Mannheimer, Buster, et al.
Publicado: (2015)

Model‐based assessments of CYP3A‐mediated drug‐drug interaction risk of milademetan
por: Hong, Ying, et al.
Publicado: (2021)

Model-Based Exposure–Response Analysis of Apixaban to Quantify Bleeding Risk in Special Populations of Subjects Undergoing Orthopedic Surgery
por: Leil, T A, et al.
Publicado: (2014)

Clinical Evaluation Based on a New Approach to Improve the Accuracy of 4β-Hydroxycholesterol Measurement as a Biomarker of CYP3A4 Activity
por: Taya, Yuki, et al.
Publicado: (2023)

Pregnancy Increases CYP3A Enzymes Activity as Measured by the 4β-Hydroxycholesterol/Cholesterol Ratio
por: Mlugu, Eulambius M., et al.
Publicado: (2022)

Modeling and simulation of the endogenous CYP3A induction marker 4β-hydroxycholesterol during enasidenib treatment
por: Li, Yan, et al.
Publicado: (2019)

Sensitive UHPLC-MS/MS quantification method for 4β- and 4α-hydroxycholesterol in plasma for accurate CYP3A phenotyping
por: Suzuki, Yosuke, et al.
Publicado: (2022)

Formation of CYP3A‐specific metabolites of ibrutinib in vitro is correlated with hepatic CYP3A activity and 4β‐hydroxycholesterol/cholesterol ratio
por: Lee, Jonghwa, et al.
Publicado: (2022)

CYP3A Activity in End-of-Life Cancer Patients Measured by 4β-Hydroxycholesterol/cholesterol Ratio, in Men and Women
por: Bergström, Helena, et al.
Publicado: (2021)

Utility of endogenous 4β-hydroxycholesterol as a biomarker to assess cytochrome P 450 3A (CYP3A) activity: not quite ready for prime time
por: Tung, Norint P., et al.
Publicado: (2022)

PXR and 4β-Hydroxycholesterol Axis and the Components of Metabolic Syndrome
por: Hukkanen, Janne, et al.
Publicado: (2020)

Serum 4β-hydroxycholesterol increases during fluconazole treatment
por: Lütjohann, Dieter, et al.
Publicado: (2020)

Response to: “Utility of endogenous 4β-hydroxycholesterol as a biomarker to assess cytochrome P 450 3A (CYP3A) activity: not quite ready for prime time”
por: Kvitne, Kine Eide, et al.
Publicado: (2022)

Elevated 4β‐hydroxycholesterol/cholesterol ratio in anorexia nervosa patients
por: Hole, Kristine, et al.
Publicado: (2018)

4β-Hydroxycholesterol Signals From the Liver to Regulate Peripheral Cholesterol Transporters
por: Salonurmi, Tuire, et al.
Publicado: (2020)

Characterization of Renal Glucose Reabsorption in Response to Dapagliflozin in Healthy Subjects and Subjects With Type 2 Diabetes
por: DeFronzo, Ralph A., et al.
Publicado: (2013)

Excitotoxicity increases the release of 24S-hydroxycholesterol via CYP46A1 activation
por: Sodero, Alejandro, et al.
Publicado: (2013)

Correlations between 4β-hydroxycholesterol and hepatic and intestinal CYP3A4: protein expression, microsomal ex vivo activity, and in vivo activity in patients with a wide body weight range
por: Eide Kvitne, Kine, et al.
Publicado: (2022)

Flexible and efficient Bayesian pharmacometrics modeling using Stan and Torsten, Part I
por: Margossian, Charles C., et al.
Publicado: (2022)

Metaheuristics for pharmacometrics
por: Kim, Seongho, et al.
Publicado: (2021)

Translational Biomedical Informatics and Pharmacometrics Approaches in the Drug Interactions Research
por: Zhang, Pengyue, et al.
Publicado: (2018)

Pregnane X Receptor‒4β‐Hydroxycholesterol Axis in the Regulation of Overweight‐ and Obesity‐Induced Hypertension
por: Rahunen, Roosa, et al.
Publicado: (2022)

Circulating 27-hydroxycholesterol and breast cancer tissue expression of CYP27A1, CYP7B1, LXR-β, and ERβ: results from the EPIC-Heidelberg cohort
por: Le Cornet, Charlotte, et al.
Publicado: (2020)

A Bayesian Perspective on Estimation of Variability and Uncertainty in Mechanism-Based Models
por: Leil, T A
Publicado: (2014)

Pharmacometrics: Focus on the Patient
por: Dumitrescu, T Pene, et al.
Publicado: (2015)

Commentary on Pharmacometrics for Immunotherapy
por: Garrido, MJ, et al.
Publicado: (2017)

Pharmacometrics and/or Systems Pharmacology
por: van der Graaf, Piet H.
Publicado: (2019)

Interactive Pharmacometric Applications Using R and the Shiny Package
por: Wojciechowski, J, et al.
Publicado: (2015)

The status of pharmacometrics in pregnancy: highlights from the 3(rd) American conference on pharmacometrics
por: van Hasselt, J G Coen, et al.
Publicado: (2012)

The utility of endogenous glycochenodeoxycholate-3-sulfate and 4β-hydroxycholesterol to evaluate the hepatic disposition of atorvastatin in rats
por: Ma, Yanrong, et al.
Publicado: (2021)

Improving pharmacometrics analysis efficiency using DataCheQC: An interactive, Shiny‐based app for quality control of pharmacometrics datasets
por: Dotan, Or, et al.
Publicado: (2023)

Bioequivalence of saxagliptin/dapagliflozin fixed‐dose combination tablets compared with coadministration of the individual tablets to healthy subjects
por: Vakkalagadda, Blisse, et al.
Publicado: (2016)

Inhibition of pathogenic non-enveloped viruses by 25-hydroxycholesterol and 27-hydroxycholesterol
por: Civra, Andrea, et al.
Publicado: (2014)

Population Pharmacokinetics of Apixaban in Subjects With Nonvalvular Atrial Fibrillation
por: Cirincione, Brenda, et al.
Publicado: (2018)

Incorporating Pharmacometrics into Pharmacoeconomic Models: Applications from Drug Development
por: Srinivasan, Meenakshi, et al.
Publicado: (2020)

Model‐Based Evaluation of Exenatide Effects on the QT Interval in Healthy Subjects Following Continuous IV Infusion
por: Cirincione, Brenda, et al.
Publicado: (2017)

CPT: Pharmacometrics and Systems Pharmacology
por: van der Graaf, Piet H
Publicado: (2012)

Opinion: The Pharmacometrics of Infectious Disease
por: Davies, G R, et al.
Publicado: (2013)

Pharmacometric Characterization of Dabigatran Hemodialysis
por: Liesenfeld, Karl-Heinz, et al.
Publicado: (2013)

CPT: Pharmacometrics & Systems Pharmacology
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_3vu1am4mcgpd8b6pikbs10nhe2